Dr. Hay’s research is focused on the central nervous system control of cardiovascular regulation. The primary emphasis is on understanding the biophysical and cellular mechanisms underlying neurotransmitter and hormone modulation of brainstem neurons and sympathetic outflow and, ultimately, how those actions affect arterial blood pressure and hypertension. Current efforts are focused are the development of novel neuroprotective peptide therapies for treatment of cognitive dysfunction in patients with cardiovascular disease. Dr. Hay’s recent discovery of a novel neuroprotective peptide has led to the creation of a new biotechnology company, ProNeurogen, Inc, where she currently serves as President, CEO and co-founder.
The Tucson Myofilament Meeting is an international 3.5-day Sarver Heart Center conference that brings together approximately 250 scientists focused on the structure and function of the myofilaments that comprise the contractile machinery of muscle. Spanning topics from molecular biophysics to heart and skeletal muscle disease mechanisms and drug development, the meeting is known for its highly interactive, collaborative, and informal atmosphere, with strong engagement of early career investigators.
Traditionally held biennially at the University of Wisconsin, the meeting will continue at the University of Arizona beginning in May 2026, offering a distinctive Tucson setting that fosters scientific exchange and community building.